Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
6-(1H-indol-4-yl)-4-(5-{[4-1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hemi succinate salt, polymorphs and pharmaceutical compositions thereof
US8993576B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993576-B2 |
| Application number | US-201113879667-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 25, 2011 |
| Priority date | Oct 27, 2010 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to a polymorph of a compound and salts of a compound and polymorphs thereof, which compound is an inhibitor of kinase activity.
First claim
Opening claim text (preview).
What is claimed is: 1. 6-(1H-Indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hemi succinate. 2. A polymorph of the hemi succinate salt of 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole characterized in that it provides an XRPD pattern comprising peaks (°2θ) at about 7.2, about 13.2 and/or about 14.0. 3. A polymorph according to claim 2 characterized in that it provides an XRPD pattern comprising peaks substantially as set out in Table 4. 4. A pharmaceutical composition comprising a salt as defined in claim 1 and one or more pharmaceutically acceptable excipients.
Assignees
Inventors
Classifications
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Drugs for immunological or allergic disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8993576B2 cover?
- The present invention is directed to a polymorph of a compound and salts of a compound and polymorphs thereof, which compound is an inhibitor of kinase activity.
- Who is the assignee on this patent?
- Hamblin Julie Nicole, Jones Paul Spencer, Keeling Suzanne Elaine, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification C07D413/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).